Analysts

Eli Lilly Outperforms Novo Nordisk as Market Confidence Diverges Following Earnings Reports

08/06/2026, 07:41 AM business review healthcare Novo Nordisk Eli Lilly

Eli Lilly and Novo Nordisk reported strong second-quarter earnings, but investor reactions diverged significantly, highlighting a growing confidence gap between the two companies in the competitive obesity drug market.

Analysts Evercore ISI see 45% upside for DoorDash (DASH) with $300 price target

08/06/2026, 07:41 AM investing rating_growth Analysts: analysts, Evercore ISI internet DoorDash

DoorDash is experiencing significant order growth, driven by its expanding subscriber base, which has led Evercore ISI to project a 45% upside for the stock, indicating a positive outlook for investors.

Analysts Fundstrat Capital’s Tom Lee forecasts S&P 500 to reach 8,000 in August, citing strong earnings momentum

08/06/2026, 07:41 AM forecast Analysts: analysts finance

Tom Lee of Fundstrat Capital forecasts a potential rise in the S&P 500 to between 7,900 and 8,000 this August, driven by strong earnings and positive market momentum. This prediction suggests a further upside of 2.3% to 3.6% from recent levels.

Analysts JPMorgan upgraded Celanese (CE) target price to $76, citing strong long-term investment potential

08/06/2026, 07:41 AM rating_growth Analysts: analysts, JPMorgan Celanese

JPMorgan has added Celanese to its focus list, highlighting its potential for significant upside due to expected earnings growth in its Acetyl Chain segment, despite current investor concerns over its financial leverage.

Analysts Piper Sandler downgraded Applovin (APP) to Neutral and slashed target price to $385 following Q2 revenue miss

08/06/2026, 06:41 AM economy rating_drop Analysts: analysts, Piper Sandler ai AppLovin

Applovin's shares dropped 17% after the company reported second-quarter revenue that fell short of Wall Street expectations, highlighting challenges in its advertising model improvements.

Analysts JPMorgan upgraded Charles River Laboratories (CRL) to overweight and raised target price to $310, expecting 19% upside

08/06/2026, 06:41 AM investing rating_growth Analysts: analysts, JPMorgan biotech Charles River Laboratories

JPMorgan has upgraded Charles River Laboratories to overweight, raising its price target significantly, as the company benefits from a resurgence in biotechnology investments and strong quarterly earnings.

Analysts Mizuho caution on potential pressure for SpaceX (SPACE) stock as first batch of shares unlocks post-IPO

08/06/2026, 05:37 AM economy review Analysts: analysts, Mizuho SpaceX

The expiration of lockup restrictions for early SpaceX investors could lead to increased selling pressure on the stock, which has already seen a significant decline since its IPO. This event is critical for investors to monitor as it may influence the stock's price trajectory in the near term.

Analysts Piper Sandler downgraded AppLovin (APP) to Neutral and lowered target price to $385, indicating 7.9% downside

08/06/2026, 04:36 AM investing rating_drop Analysts: analysts, Piper Sandler software AppLovin

Piper Sandler has downgraded AppLovin's stock from overweight to neutral, significantly reducing its price target, following a mixed second-quarter report and disappointing profit guidance for the third quarter. This downgrade reflects concerns about the company's ability to meet future expectations despite its previous strong performance.

AstraZeneca Considers Merger Talks with Bristol Myers Squibb, Challenging Decade-Long Pharma Strategy

08/06/2026, 03:36 AM business review AstraZeneca

AstraZeneca's reported merger talks with Bristol Myers Squibb signal a potential shift in the pharmaceutical industry's strategy, moving away from smaller acquisitions to larger-scale mergers. This could reshape AstraZeneca's market position but also presents significant integration and regulatory challenges.

Hadrian Secures Nearly $8 Billion Valuation Following Latest Funding Round Led by Baillie Gifford and J.P. Morgan

08/06/2026, 03:36 AM economy fundraising defense ai JPMorgan Chase

Hadrian, a manufacturing startup focused on defense technology, has raised funding that values the company at nearly $8 billion, reflecting a significant increase in investor interest in the defense sector amid rising geopolitical tensions.